December 2022 THE EUFOREA POCKET GUIDE FOR CHRONIC RHINOSINUSITISAbstract
Chronic rhinosinusitis (CRS) is known to affect around 5 % of the total population, with major impact on the quality of life of those severely affected (1). Despite a substantial burden on individuals, society and health economies, CRS often remains underdiagnosed, under-estimated and under-treated (2). International guidelines like the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) (3) and the International Consensus statement on Allergy and Rhinology: Rhinosinusitis 2021 (ICAR) (4) offer physicians insight into the recommended treatment options for CRS, with an overview of effective strategies and guidance of diagnosis and care throughout the disease journey of CRS. This abstract was originally published in the Rhinology on December 12, 2022. |
Robert C Kern, MD, chairman of the Department of Otolaryngology - Head and Neck Surgery, and George A. Sisson, MD Professor of Otolaryngology at Northwestern University's Feinberg School of Medicine, was corresponding author of the study published in Genome Medicine.
Refer a PatientNorthwestern Medicine welcomes the opportunity to partner with you in caring for your patients.
|